RT Journal Article
T1 Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients.
A1 Martín-Aguilar, Lorena
A1 Camps-Renom, Pol
A1 Lleixà, Cinta
A1 Pascual-Goñi, Elba
A1 Díaz-Manera, Jordi
A1 Rojas-García, Ricardo
A1 De Luna, Noemi
A1 Gallardo, Eduard
A1 Cortés-Vicente, Elena
A1 Muñoz, Laia
A1 Alcolea, Daniel
A1 Lleó, Alberto
A1 Casasnovas, Carlos
A1 Homedes, Christian
A1 Gutiérrez-Gutiérrez, Gerardo
A1 Jimeno-Montero, María Concepción
A1 Berciano, José
A1 Sedano-Tous, María José
A1 García-Sobrino, Tania
A1 Pardo-Fernández, Julio
A1 Márquez-Infante, Celedonio
A1 Rojas-Marcos, Iñigo
A1 Jericó-Pascual, Ivonne
A1 Martínez-Hernández, Eugenia
A1 Morís de la Tassa, Germán
A1 Domínguez-González, Cristina
A1 Illa, Isabel
A1 Querol, Luis
AB To study baseline serum neurofilament light chain (sNfL) levels as a prognostic biomarker in Guillain-Barré syndrome (GBS). We measured NfL in serum (98 samples) and cerebrospinal fluid (CSF) (24 samples) of patients with GBS prospectively included in the International GBS Outcome Study (IGOS) in Spain using single-molecule array (SiMoA) and compared them with 53 healthy controls (HCs). We performed multivariable regression to analyse the association between sNfL levels and functional outcome at 1 year. Patients with GBS had higher NfL levels than HC in serum (55.49 pg/mL vs 9.83 pg/mL, p319 pg/mL), inability to run (>248 pg/mL) and ability to run (248 pg/mL) and ability to run ( Baseline sNfL levels are increased in patients with GBS, are associated with disease severity and axonal variants and have an independent prognostic value in patients with GBS.
YR 2020
FD 2020-11-05
LK http://hdl.handle.net/10668/16560
UL http://hdl.handle.net/10668/16560
LA en
DS RISalud
RD Apr 5, 2025